|1.||Honn, Kenneth V: 11 articles (09/2014 - 01/2002)|
|2.||Honn, K V: 8 articles (07/2013 - 03/2000)|
|3.||Nie, D: 6 articles (07/2013 - 03/2000)|
|4.||Nadler, Jerry L: 5 articles (03/2015 - 03/2002)|
|5.||Nie, Daotai: 5 articles (09/2014 - 01/2003)|
|6.||Jankun, Jerzy: 5 articles (01/2014 - 05/2006)|
|7.||Skrzypczak-Jankun, Ewa: 4 articles (01/2014 - 05/2006)|
|8.||Tang, Keqin: 4 articles (07/2006 - 01/2003)|
|9.||Zacharek, Alex: 4 articles (07/2006 - 01/2003)|
|10.||Pidgeon, Graham P: 4 articles (07/2003 - 05/2002)|
04/01/2000 - "Third, an inhibitor of 12-lipoxygenase has been found effective against metastatic prostate tumor growth, and the inhibition of 12-lipoxygenase is related with the reduction of tumor angiogenesis. "
01/01/2015 - "Literature search was performed in Pubmed, Embase and other databases for studies evaluating the association between the Gln261Arg polymorphism in 12-lipoxygenase gene and cancer risk. "
01/01/2015 - "Many studies suggest that the Gln261Arg polymorphism in 12-lipoxygenase gene is assicated with cancer susceptibility, but the results are inconclusive. "
01/01/2015 - "This meta-analysis suggests that the Gln261Arg polymorphism in 12-lipoxygenase gene contributes to cancer susceptibility, specifically in Asian populations. "
01/01/2015 - "This meta-analysis aimed to investigate the overall association between the Gln261Arg polymorphism in 12-lipoxygenase gene and cancer risk. "
|2.||Breast Neoplasms (Breast Cancer)
10/01/2006 - "Also it has been recorded that human breast cancer expresses high level of cox-2 and 12-lipoxygenase which may be beneficial in future therapy plan for those patients. "
10/01/2006 - "Elevated levels of cox-2 and 12-lipoxygenase expression were detected in human breast cancer. "
01/01/2005 - "Compounds 2, 3, and 4 were evaluated for their ability to inhibit the enzyme 12-lipoxygenase and 3 and 4 showed moderate activity at 30 microg/ml. Compound 2 was evaluated against a panel of colorectal and breast cancer cell lines and IC50 values ranged from 5.8 to 37.6 microg/ml. Against a panel of fast-growing mycobacteria and a standard ATCC strain of Staphylococcus aureus, compound 6 exhibited minimum inhibitory concentrations in the range of 64-128 microg/ml."
09/09/1999 - "Furthermore, the data suggest an anti-carcinogenic action of 12-lipoxygenase in human cervix, in contrast to its reported pro-carcinogenic action in breast cancer."
10/23/1998 - "Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice."
08/06/1991 - "Improved purification of 12-lipoxygenase from rat basophilic leukemia cells and conditions for optimal enzyme activity."
09/22/1992 - "12-Lipoxygenase from rat basophilic leukemia cells has many features in common with 12-lipoxygenase from bovine leukocytes. "
09/22/1992 - "Rat basophilic leukemia cells exhibit 12-lipoxygenase activity only upon cell disruption. "
09/22/1992 - "12-Lipoxygenase from rat basophilic leukemia cells, an oxygenase with leukotriene A4-synthase activity."
08/06/1991 - "12-Lipoxygenase from rat basophilic leukemia cells was purified about 300-fold by protein-HPLC in a single run. "
03/01/2015 - "Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes."
03/01/2015 - "12-Lipoxygenase (12-LO) induces inflammation and has been implicated in diabetes development. "
04/01/1999 - "The availability of new specific inhibitors and murine lines that lack expression of the homologous 12-lipoxygenase will allow confirmation of many of these effects with in vivo models of inflammation."
05/01/2013 - "Previously, we observed significant increases in spinal 12-lipoxygenase (LOX) metabolites, in particular, hepoxilins, which contribute to peripheral inflammation-induced tactile allodynia. "
05/11/2004 - "The functional significance of hepA(3) to target PMNs to the lumen of the gut at sites of inflammation was demonstrated by the finding that disruption of the 12-lipoxygenase pathway (required for hepA(3) production) could dramatically reduce PMN-mediated tissue trauma, demonstrating that hepA(3) is a key regulator of mucosal inflammation."
|5.||Prostatic Neoplasms (Prostate Cancer)
09/01/2014 - "[Selective 12-lipoxygenase inhibition potentiates the effect of radiation on human prostate cancer cells in vitro and in vivo]."
07/28/2013 - "Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase."
01/01/2013 - "The concentration of 12-lipoxygenase in platelet rich plasma as an indication of cancer of the prostate."
04/01/2011 - "The presence of arachidonate 12-lipoxygenase (12-LOX) potentiates prostate cancer (PCa) progression and therefore may be a good therapeutic target and/or a potential diagnostic predictor for PCa. "
04/01/2011 - "Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells."
|1.||Cyclooxygenase 2 (Cyclooxygenase-2)
|2.||Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)
|3.||Arachidonate 12-Lipoxygenase (12 Lipoxygenase)
|4.||Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)
|5.||NF-kappa B (NF-kB)
|8.||NADPH Oxidase (NAD(P)H oxidase)
|9.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)